3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Phase 1
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
20
Sarcoma
3
Other solid neoplasm
3
Tumor-Agnostic
2
Thoracic
2
Head & Neck
2
Genitourinary
2
NET
1
Gynecologic
1
Endocrine
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Turcot syndrome
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Tertiary Lymphoid Structures
1
Stomach Neoplasms
1
Sarcoma
1
Neoplasm Metastasis
1
Mesothelioma, Malignant
1
Gastro-enteropancreatic neuroendocrine tumor
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Biliary Tract Neoplasms
1
Interventions
Trastuzumab
72
Paclitaxel
63
Cyclophosphamide
56
pembrolizumab
53
Fulvestrant
42
Carboplatin
40
Capecitabine
37
Docetaxel
32
Letrozole
27
Doxorubicin
23
palbociclib
21
pertuzumab
20
Nivolumab
18
eribulin
17
abemaciclib
17
ribociclib
16
Gemcitabine
16
130-nm albumin-bound paclitaxel
16
durvalumab
15
Everolimus
15
Albumin-Bound Paclitaxel
15
sacituzumab govitecan
14
Lapatinib
14
Filgrastim
14
fludarabine
13
exemestane
13
Taxes
13
Bevacizumab
13
Cisplatin
12
olaparib
11
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
regorafenib
×
Breast
×
Clear all
NCT03475953
2023-03-03
REGOMUNE
Institut Bergonié
Phase 1/2
Unknown
747 enrolled